Inventiva S.A. has a strongly bullish consensus sentiment with Buy ratings from all 9 analysts covering the stock, and a 1-year median price target of $15.75 implying an upside potential of over 325%. On June 12, the company fully repaid roughly €62 million of its existing EIB loans, including principal and accrued interest, and executed a buyback and cancellation of warrants linked to around 22.7 million EIB shares for a total repurchase price of €50 million, covering all Tranche A warrants and 700,000 Tranche B warrants. Inventiva also drew down €75 million in debt financing from lenders Claret Capital Partners and BlackRock, consisting of €35 million in Tranche A Senior Secured Convertible Debt and €40 million in Tranche B Senior Secured Amortized Debt, with a conversion price of €5.2893 on the Tranche A Convertible Bonds representing a 40% premium on the EURO-denominated offer price for the stock ADS. The company is a clinical-stage biopharmaceutical firm developing oral small-molecule therapies including Odiparcil and Lanifibranor, as well as a TGF-ß treatment for idiopathic pulmonary fibrosis.
Inventiva S.AAll 9 analysts rate Buy with median price target $15.75, implying >325% upside; company also refinanced debt and bought back warrants.